Skip to content
OpenCapital
Get started

CareDx CDNA Reportable Segment — Stock-based compensation expense

Similar metrics at other companies

Hinge Health, Inc. logo
HNGEReportable Segment — Stock-based compensation expense
$11.69M+166,929%
BioCryst Pharmaceuticals logo
BCRXReportable Segment — Stock-based compensation expense
$16.03M-25.0%
Archer Aviation logo
ACHRReportable Segment — Stock-based compensation expense
$70.4M+134%
Dolby Laboratories, Inc. logo
DLBReportable Segment — Stock-based compensation expense
$30.71M+0.1%
Twist Bioscience Corporation logo
TWSTReportable Segment — Stock-based compensation expense
$18.94M-6.8%
Enphase Energy logo
ENPHReportable Segment — Stock-based compensation expense
$48.99M-11.9%

Other financials

Income statement

See full
Revenue$117.7M+39.0%
Operating income$1.2M+109%
Net income$2.8M+127%
EPS (diluted)$0.05+126%

Balance sheet

See full
Cash & equivalents$78.5M-12.1%
Total debt$24.5M-19.1%
Total equity$313.5M-17.3%
Total assets$411.1M-16.0%

Cash flow

See full
Operating cash flow$4.3M+116%
CapEx$3.8M+134%
Free cash flow$514.0K+102%

Valuation

See full
Market cap$1.4B+32.2%
Enterprise value$1.35B+34.6%
P/S3.4×+0.3×

Profitability

See full
Gross margin65.5%—
Operating margin-3.9%-18.3pp
Net margin-2%-19.9pp
FCF margin-0%0.0pp

Returns & leverage

See full
Return on equity-2.4%-21.9pp
Debt / equity0.1×0.0×
Current ratio3.4×-0.7×

Where this comes from

Reported directly by CareDx in its filing.

Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.

The official record: CareDx’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about CareDx's reportable segment — stock-based compensation expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CareDx's reportable segment — stock-based compensation expense?
CareDx (CDNA) reported reportable segment — stock-based compensation expense of $9.77M in Q1 2026.
How has CareDx's reportable segment — stock-based compensation expense changed year-over-year?
CareDx's reportable segment — stock-based compensation expense increased by 9.4% year-over-year, from $8.93M to $9.77M.
What is the long-term trend for CareDx's reportable segment — stock-based compensation expense?
Over 3 years (2022 to 2025), CareDx's reportable segment — stock-based compensation expense has grown at a -9.2% compound annual growth rate (CAGR), from $46.55M to $34.86M.
What does reportable segment — stock-based compensation expense mean?
Reflects the non-cash expense recognized for equity-based awards granted to employees and management within the segment. This metric is critical for evaluating the true cost of human capital and the alignment of management incentives with shareholder interests.